Stock analysts at Roth Capital lifted their price objective on shares of EnteroMedics (NASDAQ:ETRM) from $2.00 to $3.00 in a report issued on Wednesday, AnalystRatingsNetwork.com reports. Roth Capital’s target price would indicate a potential upside of 54.64% from the company’s current price.
Shares of EnteroMedics (NASDAQ:ETRM) traded down 13.39% on Wednesday, hitting $1.94. 9,328,392 shares of the company’s stock traded hands. EnteroMedics has a one year low of $0.81 and a one year high of $3.23. The stock’s 50-day moving average is $1.37 and its 200-day moving average is $1.20. The company’s market cap is $117.7 million.
EnteroMedics (NASDAQ:ETRM) last released its earnings data on Thursday, October 31st. The company reported ($0.11) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.11). Analysts expect that EnteroMedics will post $-0.47 EPS for the current fiscal year.
ETRM has been the subject of a number of other recent research reports. Analysts at Northland Securities raised their price target on shares of EnteroMedics from $3.00 to $7.00 in a research note to investors on Tuesday. They now have an “average” rating on the stock. Separately, analysts at Northland Capital Partners raised their price target on shares of EnteroMedics from $3.00 to $7.00 in a research note to investors on Tuesday. They now have an “outperform” rating on the stock. Finally, analysts at Lake Street Capital initiated coverage on shares of EnteroMedics in a research note to investors on Tuesday, October 15th. They set a “buy” rating and a $3.00 price target on the stock. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. EnteroMedics currently has an average rating of “Buy” and an average target price of $4.60.
EnteroMedics Inc (NASDAQ:ETRM) is a development- stage medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.